<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prevalence of <z:hpo ids='HP_0001513'>obesity</z:hpo> has increased dramatically in recent decades, both in the US and worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is a paucity of pharmacologic agents approved for the treatment of <z:hpo ids='HP_0001513'>obesity</z:hpo>, and the use of existing <z:hpo ids='HP_0001824'>weight loss</z:hpo> medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost </plain></SENT>
<SENT sid="3" pm="."><plain>In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight </plain></SENT>
<SENT sid="4" pm="."><plain>One such hormone, GLP-1, also plays an important role in <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis </plain></SENT>
<SENT sid="5" pm="."><plain>GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>There has also been interest in the use of GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> for the treatment of <z:hpo ids='HP_0001513'>obesity</z:hpo> in nondiabetic patients </plain></SENT>
<SENT sid="7" pm="."><plain>This review explores the potential utility and limitations of exenatide and liraglutide as therapeutic agents for <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
</text></document>